Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer

Rachel A. Freedman, MD, MPH
Published: Thursday, Jun 29, 2017



Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.

Targeting dual anti-HER2 targeting therapy is attractive, says Freedman, especially ONT-380, which does not have as many adverse events as seen with therapies such as neratinib (Nerlynx).
 


Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.

Targeting dual anti-HER2 targeting therapy is attractive, says Freedman, especially ONT-380, which does not have as many adverse events as seen with therapies such as neratinib (Nerlynx).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x